StockNews.com Upgrades Oramed Pharmaceuticals (NASDAQ:ORMP) to “Hold”

Oramed Pharmaceuticals (NASDAQ:ORMP) was upgraded by StockNews.com from a “sell” rating to a “hold” rating in a research note issued to investors on Wednesday.

Separately, HC Wainwright reissued a “neutral” rating on shares of Oramed Pharmaceuticals in a research report on Monday, September 9th.

Oramed Pharmaceuticals Trading Up 3.8 %

Shares of NASDAQ ORMP opened at $2.49 on Wednesday. The stock has a market capitalization of $100.38 million, a PE ratio of 22.64 and a beta of 1.70. Oramed Pharmaceuticals has a 12-month low of $2.00 and a 12-month high of $3.67. The stock’s fifty day simple moving average is $2.38 and its two-hundred day simple moving average is $2.39.

Institutional Trading of Oramed Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the stock. Dimensional Fund Advisors LP grew its stake in Oramed Pharmaceuticals by 52.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 31,470 shares of the biotechnology company’s stock valued at $81,000 after purchasing an additional 10,774 shares during the last quarter. Renaissance Technologies LLC boosted its position in Oramed Pharmaceuticals by 89.0% in the second quarter. Renaissance Technologies LLC now owns 230,800 shares of the biotechnology company’s stock valued at $593,000 after buying an additional 108,700 shares during the last quarter. XTX Topco Ltd acquired a new position in Oramed Pharmaceuticals in the 2nd quarter worth approximately $40,000. Murchinson Ltd. raised its position in Oramed Pharmaceuticals by 23.2% during the 2nd quarter. Murchinson Ltd. now owns 1,699,990 shares of the biotechnology company’s stock worth $4,369,000 after buying an additional 320,495 shares during the last quarter. Finally, BML Capital Management LLC raised its position in Oramed Pharmaceuticals by 62.1% during the 3rd quarter. BML Capital Management LLC now owns 2,186,191 shares of the biotechnology company’s stock worth $5,334,000 after buying an additional 837,153 shares during the last quarter. 12.73% of the stock is currently owned by institutional investors and hedge funds.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.